autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT00278200)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
Immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05882305 | Early Phase 1 (Phase 1) | Jun 10, 2023 | Changhai Hospital, Kousai Bio Co., Ltd. |
| NCT05635591 | Phase 1 | Dec 5, 2022 | Huazhong University of Science and Technology, Kousai Bio Co., Ltd. |
| NCT00278200 | Phase 1 | Sep 1, 2002 | Johns Hopkins University, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kousai Bio Co., Ltd. | For profit | 2 | 1 | 1 | 2022 |
| Changhai Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2002 |
5 organizations
Page 1 / 1